Upasna Srivastava

Dr. Upasna Srivastava

Department of Neurology, Yale University, New Haven, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Stem Cell Reports
Verified
Journal Article
Open access
TOTakuya Okamoto
Takuya Okamoto
DDDavid Duverle
David Duverle
KYKatsuyuki Yaginuma
Katsuyuki Yaginuma
YNYasuko Natsume
Yasuko Natsume
HYHitomi Yamanaka
Hitomi Yamanaka
RYRyoji Yao
Ryoji Yao
Metastasis is the major cause of cancer-related death, but whether metastatic lesions exhibit the same cellular composition as primary tumors has yet to be elucidated. To investigate the cellular heterogeneity of metastatic colorectal cancer (CRC), we established 72 patient-derived organoids (PDOs) from 21 patients. Combined bulk transcriptomic and single-cell RNA-sequencing analysis revealed decreased gene expression of markers for differentiated cells in PDOs derived from metastatic lesions. Paradoxically, expression of potential intestinal stem cell markers was also decreased. We identified OLFM4 as the gene most strongly correlating with a stem-like cell cluster, and found OLFM4+ cells to be capable of initiating organoid culture growth and differentiation capacity in primary PDOs. These cells were required for the efficient growth of primary PDOs but dispensable for metastatic PDOs. These observations demonstrate that metastatic lesions have a cellular composition distinct from that of primary tumors; patient-matched PDOs are a useful resource for analyzing metastatic CRC.

10 May 2024
Verified
Book Chapter
Closed access
USUpasna Srivastava
Upasna Srivastava
SKSwarna K.
Swarna K.
MKMinu Kesheri
Minu Kesheri
MANISH GUPTAMANISH GUPTA
MANISH GUPTA
DSDr. Satendra Singh
Dr. Satendra Singh
1

25 October 2023
Verified
Book Chapter
Closed access
PDF file
USUpasna Srivastava
Upasna Srivastava
SKSwarna K.
Swarna K.
MKMinu Kesheri
Minu Kesheri
SSSatendra Singh
Satendra Singh
1

10 May 2024
Verified
Book Chapter
Closed access
USUpasna Srivastava
Upasna Srivastava
SKSwarna K.
Swarna K.
MKMinu Kesheri
Minu Kesheri
MGManish Kumar Gupta
Manish Kumar Gupta
SSSatendra Singh
Satendra Singh

5 January 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
MSMizuho Sakahara
Mizuho Sakahara
TOTakuya Okamoto
Takuya Okamoto
USUpasna Srivastava
Upasna Srivastava
YNYasuko Natsume
Yasuko Natsume
HYHitomi Yamanaka
Hitomi Yamanaka
RYRyoji Yao
Ryoji Yao
Tumor tissues consist of heterogeneous cells that originate from stem cells; however, their cell fate determination program remains incompletely understood. Using patient-derived organoids established from patients with advanced colorectal cancer (CRC), we evaluated the potential of olfactomedin 4 (OLFM4)+ stem cells to produce a bifurcated lineage of progenies with absorptive and secretory properties. In the early phases of organoid reconstruction, OLFM4+ cells preferentially gave rise to secretory cells. Additionally, we found that Paneth-like cells, which do not exist in the normal colon, were induced in response to Notch signaling inhibition. Video recordings of single OLFM4+ cells revealed that organoids containing Paneth-like cells were effectively propagated and that their selective ablation led to organoid collapse. In tumor tissues, Paneth-like cells were identified only in the region where tumor cells lost cell adhesion. These findings indicate that Paneth-like cells are directly produced by OLFM4+ stem cells and that their interaction contributes to tumor formation by providing niche factors. This study reveals the importance of the cell fate specification program for building a complete tumor cellular ecosystem, which might be targeted with novel therapeutics.

4 November 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
RSRINKU SHARMA
RINKU SHARMA
ATAnshul Tiwari
Anshul Tiwari
AKAlvin T. Kho
Alvin T. Kho
AWAlberta L. Wang
Alberta L. Wang
USUpasna Srivastava
Upasna Srivastava
MMMichael J. McGeachie
Michael J. McGeachie
Bronchodilator response (BDR) is a measure of improvement in airway smooth muscle tone, inhibition of liquid accumulation and mucus section into the lumen in response to short-acting beta-2 agonists that varies among asthmatic patients. MicroRNAs (miRNAs) are well-known post-translational regulators. Identifying miRNAs associated with BDR could lead to a better understanding of the underlying complex pathophysiology. The purpose of this study is to identify circulating miRNAs associated with bronchodilator response in asthma and decipher possible mechanism of bronchodilator response variation. We used available small RNA sequencing on blood serum from 1,134 asthmatic children aged 6 to 14 years who participated in the Genetics of Asthma in Costa Rica Study (GACRS). We filtered the participants into the highest and lowest bronchodilator response (BDR) quartiles and used DeSeq2 to identify miRNAs with differential expression (DE) in high (N = 277) vs. low (N = 278) BDR group. Replication was carried out in the Leukotriene modifier Or Corticosteroids or Corticosteroid-Salmeterol trial (LOCCS), an adult asthma cohort. The putative target genes of DE miRNAs were identified, and pathway enrichment analysis was performed. We identified 10 down-regulated miRNAs having odds ratios (OR) between 0.37 and 0.76 for a doubling of miRNA counts and one up-regulated miRNA (OR = 2.26) between high and low BDR group. These were assessed for replication in the LOCCS cohort, where two miRNAs (miR-200b-3p and miR-1246) were associated. Further, functional annotation of 11 DE miRNAs were performed as well as of two replicated miRs. Target genes of these miRs were enriched in regulation of cholesterol biosynthesis by SREBPs, ESR-mediated signaling, G1/S transition, RHO GTPase cycle, and signaling by TGFB family pathways. MiRNAs miR-1246 and miR-200b-3p are associated with both childhood and adult asthma BDR. Our findings add to the growing body of evidence that miRNAs play a significant role in the difference of asthma treatment response among patients as it points to genomic regulatory machinery underlying difference in bronchodilator response among patients. LOCCS cohort [ClinicalTrials.gov number NCT00156819, Registration date 20050912], GACRS cohort [ClinicalTrials.gov number NCT00021840].